Activin A and follistatin are dynamically regulated during human pregnancy
Abstract Activin A (βA–βA) and activin B (βB–βB) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent...
Saved in:
| Published in | Journal of endocrinology Vol. 152; no. 2; pp. 167 - 174 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Colchester
BioScientifica
01.02.1997
Portland Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Activin A (βA–βA) and activin B (βB–βB) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (<0·78 ng/ml (first trimester) to 1–6 ng/ml (term)). Activin B was not detected in any serum sample (<0·78 pg/ml). Total serum follistatin (free follistatin, follistatin–activin, and follistatin–inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100–450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range <2–35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin–activin (or –inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Journal of Endocrinology (1997) 152, 167–174 |
|---|---|
| AbstractList | Activin A (β A –β A ) and activin B (β B –β B ) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin,
a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent
activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for
biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection),
while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera.
The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected
samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each
person serving as an internal reference.
Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to,
but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin
(an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin,
human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific
assays.
Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor
(<0·78 ng/ml (first trimester) to 1–6 ng/ml (term)). Activin B was not detected in any serum sample (<0·78 pg/ml). Total serum
follistatin (free follistatin, follistatin–activin, and follistatin–inhibin) increased 10- to 45-fold in the final month of
pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100–450 ng/ml (final month)). Total
follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration
in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range <2–35
ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did
not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire
course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester
of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy
(inclusive of the non-laboring patient).
The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset
labor. The total follistatin assay results suggest that follistatin–activin (or –inhibin) complexes are upregulated during
the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin.
Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is
biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last
trimester of human pregnancy and may be involved in normal labor.
Journal of Endocrinology (1997) 152, 167–174 Abstract Activin A (βA–βA) and activin B (βB–βB) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (<0·78 ng/ml (first trimester) to 1–6 ng/ml (term)). Activin B was not detected in any serum sample (<0·78 pg/ml). Total serum follistatin (free follistatin, follistatin–activin, and follistatin–inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100–450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range <2–35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin–activin (or –inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Journal of Endocrinology (1997) 152, 167–174 Activin A (beta A-beta A) and activin B (beta B-beta B) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (< 0.78 ng/ml (first trimester) to 1-6 ng/ml (term)). Activin B was not detected in any serum sample (< 0.78 pg/ml). Total serum follistatin (free follistatin, follistatin-activin, and follistatin-inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100-450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range < 2-35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin-activin (or -inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Activin A (beta A-beta A) and activin B (beta B-beta B) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (< 0.78 ng/ml (first trimester) to 1-6 ng/ml (term)). Activin B was not detected in any serum sample (< 0.78 pg/ml). Total serum follistatin (free follistatin, follistatin-activin, and follistatin-inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100-450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range < 2-35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin-activin (or -inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Abstract Activin A (β A –β A ) and activin B (β B –β B ) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (<0·78 ng/ml (first trimester) to 1–6 ng/ml (term)). Activin B was not detected in any serum sample (<0·78 pg/ml). Total serum follistatin (free follistatin, follistatin–activin, and follistatin–inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100–450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range <2–35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin–activin (or –inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Journal of Endocrinology (1997) 152, 167–174 |
| Author | I Janssen E Wang T K Woodruff P Sluss M S Mersol-Barg |
| Author_xml | – sequence: 1 givenname: T. K surname: WOODRUFF fullname: WOODRUFF, T. K organization: Departments of Medicine and Neurobiology and Physiology and the Center for Reproductive Sciences, Northwestern University, Chicago, Illinois, United States – sequence: 2 givenname: P surname: SLUSS fullname: SLUSS, P organization: National Cooperative Program for Infertility Research at the Massachusetts General Hospital, Boston, Massachusetts, United States – sequence: 3 givenname: E surname: WANG fullname: WANG, E organization: Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, United States – sequence: 4 givenname: I surname: JANSSEN fullname: JANSSEN, I organization: Department of Neurology, Northwestern University, Chicago, Illinois, United States – sequence: 5 givenname: M. S surname: MERSOL-BARG fullname: MERSOL-BARG, M. S organization: Division of Reproductive Endocrinology, Henry Ford Hospital, Detroit, Michigan, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2570363$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9071973$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMFu1DAQQC1UVLYtR45IOaDeUsZOYsfHVUWhqBIXeo4m9njXVeIsdgLav8dVVj0g0ZPHM2_GnnfBzsIUiLEPHG64VOrz00Q3OWwE5OsbtuG10qVsoTljGwAhSlC6eccuUnoC4A1X1Tk716C4VtWGfd-a2f_2odgWGGzhpmHwacY5ZzBSYY8BR29wGI5FpN0y4Ey2sEv0YVfslxFDccj5gMEcr9hbh0Oi96fzkj3effl5-618-PH1_nb7UPY1yLkkbLWsSfbG1QIaJGmg58IKawxUvaGegwZ0iNpib4yuOddCuLoSzkhpq0t2vc49xOnXQmnuRp8MDQMGmpbUqbZVqq2bDJYraOKUUiTXHaIfMR47Dt2zuy6763K4usv8x9PgpR_JvtAnWbn-6VTHlJW4mLf26QUTjYJKPmP1iu39bv_HR-p6PyXjKczeZZf_fb1a2_6hX__zXx9knGM |
| CODEN | JOENAK |
| CitedBy_id | crossref_primary_10_1016_S0165_0378_98_00025_4 crossref_primary_10_1210_endo_138_7_5231 crossref_primary_10_1095_biolreprod59_2_233 crossref_primary_10_1177_107155760000700504 crossref_primary_10_1053_plac_2002_0854 crossref_primary_10_1111_j_1471_0528_2001_00202_x crossref_primary_10_1006_mcne_1999_0798 crossref_primary_10_1046_j_1365_2265_1999_00716_x crossref_primary_10_1111_j_1471_0528_2005_00791_x crossref_primary_10_1177_153537020222700905 crossref_primary_10_1067_mob_2002_121087 crossref_primary_10_1002_mus_21244 crossref_primary_10_1053_plac_2002_0831 crossref_primary_10_1111_j_1365_2265_2009_03567_x crossref_primary_10_1095_biolreprod60_1_8 crossref_primary_10_1016_S0306_5456_00_00202_3 crossref_primary_10_1111_j_1471_0528_2000_tb10402_x crossref_primary_10_1002_0471142301_ns0319s36 crossref_primary_10_1071_RD03110 crossref_primary_10_1210_endo_140_10_7072 crossref_primary_10_1016_j_anireprosci_2008_08_022 crossref_primary_10_1006_frne_1998_0169 crossref_primary_10_1016_j_cyto_2017_10_020 crossref_primary_10_1038_sj_onc_1208087 crossref_primary_10_1016_S1071_55760300047_9 crossref_primary_10_1152_physrev_00002_2018 crossref_primary_10_1177_22925503211051120 crossref_primary_10_1053_plac_2002_0840 crossref_primary_10_1210_en_2007_0692 crossref_primary_10_1210_er_2014_1003 crossref_primary_10_1016_j_placenta_2022_03_015 |
| ContentType | Journal Article |
| Copyright | 1997 INIST-CNRS |
| Copyright_xml | – notice: 1997 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1677/joe.0.1520167 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1479-6805 |
| EndPage | 174 |
| ExternalDocumentID | 10_1677_joe_0_1520167 9071973 2570363 10.1677/joe.0.1520167 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: HD29164 |
| GroupedDBID | - 02 08R 0R 2WC 3O- 4.4 53G 55 5GY 5RE 5VS AAFZV AAYJJ ABFLS ABLYK ABOCM ABPTK ABSGY ACNCT ACPRK ADACO ADBBV ADBIT ADDZX AENEX AFDAS AFFNX AGCAB ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P FA8 FH7 GJ GX1 H13 HZ H~9 IL9 INIJC J5H K-O KM KQ8 L7B MVM O0- O9- OHT OK1 P2P REN RHF TBS VH1 WH7 WOQ X X7M XJT ZA5 ZGI ZXP --- -~X .55 .GJ 0R~ 18M AAUGY ABSQV ACGFO AFHIN AFOSN AI. BTFSW F9R HF~ HZ~ IQODW W8F WHG ~02 ~KM CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-b406t-ea8964e6bcf4205ae6c0b12d2dcc03bceb1090afaa9dabcc9411922f432fc66d3 |
| ISSN | 0022-0795 |
| IngestDate | Fri Aug 16 01:13:25 EDT 2024 Fri Aug 23 02:24:18 EDT 2024 Sat Sep 28 08:40:22 EDT 2024 Sun Oct 29 17:10:18 EDT 2023 Fri Jan 15 01:59:54 EST 2021 Mon Mar 15 03:18:24 EDT 2021 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Human Pregnancy Binding protein Regulation(control) Follistatin Activin Woman |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-b406t-ea8964e6bcf4205ae6c0b12d2dcc03bceb1090afaa9dabcc9411922f432fc66d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 9071973 |
| PQID | 78877845 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_78877845 crossref_primary_10_1677_joe_0_1520167 pubmed_primary_9071973 pascalfrancis_primary_2570363 highwire_bioscientifica_10_1677_joe_0_1520167 bioscientifica_primary_10_1677_joe_0_1520167 |
| ProviderPackageCode | RHF |
| PublicationCentury | 1900 |
| PublicationDate | 1997-02-01 |
| PublicationDateYYYYMMDD | 1997-02-01 |
| PublicationDate_xml | – month: 02 year: 1997 text: 1997-02-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | Colchester |
| PublicationPlace_xml | – name: Colchester – name: England |
| PublicationTitle | Journal of endocrinology |
| PublicationTitleAlternate | J Endocrinol |
| PublicationYear | 1997 |
| Publisher | BioScientifica Portland Press |
| Publisher_xml | – name: BioScientifica – name: Portland Press |
| SSID | ssj0015173 |
| Score | 1.7372572 |
| Snippet | Abstract Activin A (βA–βA) and activin B (βB–βB) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by... Activin A (β A –β A ) and activin B (β B –β B ) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by... Activin A (beta A-beta A) and activin B (beta B-beta B) are related dimeric proteins that regulate numerous cellular activities. Activin activity is... Abstract Activin A (β A –β A ) and activin B (β B –β B ) are related dimeric proteins that regulate numerous cellular activities. Activin activity is... |
| SourceID | proquest crossref pubmed pascalfrancis highwire bioscientifica |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 167 |
| SubjectTerms | Activins Adjuvants, Immunologic - blood Biological and medical sciences Enzyme-Linked Immunosorbent Assay Female Follistatin Fundamental and applied biological sciences. Psychology Glycoproteins - blood Hormone metabolism and regulation Humans Inhibins - blood Luminescent Measurements Oligopeptides Peptides - blood Pregnancy - metabolism Pregnancy Trimester, Second Pregnancy Trimester, Third Pregnancy. Parturition. Lactation Radioimmunoassay Vertebrates: reproduction |
| Title | Activin A and follistatin are dynamically regulated during human pregnancy |
| URI | http://dx.doi.org/10.1677/joe.0.1520167 http://joe.endocrinology-journals.org/content/152/2/167.abstract https://www.ncbi.nlm.nih.gov/pubmed/9071973 https://search.proquest.com/docview/78877845 |
| Volume | 152 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Bb9MwFLZgSAgkEGxMKzDwAe0C6RzbcZJjBCtTxTqJrqK3yHYSCdQl05Ydxq_nOXbSpDANuESRlThpvq_Pz_b33kPonRSacbD7XqQY8bgELFRItReDYQS-xIQqs6N7MhPHCz5dBsvejqmJLqnVWP_8Y1zJ_6AKbYCriZL9B2S7TqEBzgFfOALCcPwrjBNjrMyCRbMFUJj82iZACFqMniuzxeblanXz_tKWnAfv0sUl2tp8F9BuMm4M9nZ7PmpeZhWYlY2199PTT18Xk0kD9bi3TvplMZ8PQsa-JTYiqot2mCaz-fxotl6tzVwAXthKlB1DjMB1ZQMZ1hKRNiyAhLZi5ji31pSHsSciEgzMbUB7vKI94-nbwhxuHPZt9Z7fTLxoNpl_VPm4Kd5Eurv6qbQ3hrhOeEhtwrH76AGFVzUS0M_LThIEzo9TJLif4nKywhMPB897jJ6o7zbXaCPo2nBq2kTTRmcrrwDmwtZIuX0S0zgzZ8_QU4cwTiylnqN7ebmNdpJS1tX5DT7AjS64AX0bPTxx8osdNHWEwwkGbHCPcBgIh3uEwx3hsCUcbgiHO8K9QIvJ0dnHY88V4_AU-Hy1l8soFjwXSheckkDmQhPl04xmWhOmNIz5JCaykDLOpNI65j5MHmjBGS20EBnbRVtlVeZ7CLOIsUKwIsxgMNA8kjAqcJ8wJoUslIxH6MPw86YXNvNKamasgEYKaKRwatEYoYP24991oddCk2484Jbr9wf4db07Fo3Q2xbPFIyy2WmTZV5dX6VGogu2LhihXQtzd2sMLn0cspd3dP0KPVr_916jrfryOt8H77dWbxrK_gJpSq2h |
| link.rule.ids | 315,786,790,27955,27956 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activin+A+and+follistatin+are+dynamically+regulated+during+human+pregnancy&rft.jtitle=Journal+of+endocrinology&rft.au=WOODRUFF%2C+T.+K&rft.au=SLUSS%2C+P&rft.au=WANG%2C+E&rft.au=JANSSEN%2C+I&rft.date=1997-02-01&rft.pub=Portland+Press&rft.issn=0022-0795&rft.eissn=1479-6805&rft.volume=152&rft.issue=2&rft.spage=167&rft.epage=174&rft_id=info:doi/10.1677%2Fjoe.0.1520167&rft.externalDBID=n%2Fa&rft.externalDocID=2570363 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-0795&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-0795&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-0795&client=summon |